menu
    • menu

    Company profile for Madrigal Pharmaceuticals

    NEW Drugs in Dev: 6
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Madrigal PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    200 Barr Harbor Drive Suite 200 West Conshohocken, PA 19428
    Telephone
    Telephone
    (267) 327-4445
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.madrigalpharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    ASPEN

    ASPEN

    Not Confirmed

    envelop Contact Supplier

    ASPEN

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Madrigal Pens $4.4B Deal For siRNA Drugs In Fresh Rezdiffra Play
    Madrigal Pens $4.4B Deal For siRNA Drugs In Fresh Rezdiffra Play

    12 Feb 2026

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/madrigal-pens-44b-deal-ribos-sirna-programs-latest-rezdiffra-mash-play

    FIERCE BIOTECH
    12 Feb 2026
    Share Share
    Madrigal Pharma Awards Inducement Grants Per Nasdaq LR 5635(C)(4)
    Madrigal Pharma Awards Inducement Grants Per Nasdaq LR 5635(C)(4)

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3233445/0/en/Madrigal-Pharmaceuticals-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Madrigal Pharma To Unveil Q4 & Full-Year 2025 Finances, Webcast
    Madrigal Pharma To Unveil Q4 & Full-Year 2025 Finances, Webcast

    02 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/02/3230242/0/en/Madrigal-Pharmaceuticals-to-Release-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Host-Webcast-on-February-19-2026.html

    GLOBENEWSWIRE
    02 Feb 2026
    Share Share
    Madrigal Pharma Grants Inducements Under Nasdaq Rule 5635(c)(4)
    Madrigal Pharma Grants Inducements Under Nasdaq Rule 5635(c)(4)

    22 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/22/3224261/0/en/Madrigal-Pharmaceuticals-Announces-Grants-of-Inducement-Awards-under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    22 Jan 2026
    Share Share
    Madrigal Pharma Grants Inducement Under Nasdaq Rule 5635(c)(4)
    Madrigal Pharma Grants Inducement Under Nasdaq Rule 5635(c)(4)

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3223236/0/en/Madrigal-Pharmaceuticals-Announces-Grant-of-Inducement-Award-under-Nasdaq-Listing-Rule-5635-c-4.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    Madrigal Expands MASH Pipeline With Ervogastat Phase 2 Agreement
    Madrigal Expands MASH Pipeline With Ervogastat Phase 2 Agreement

    09 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/09/3216039/0/en/Madrigal-Expands-its-MASH-Pipeline-with-Exclusive-Global-License-Agreement-for-Ervogastat-a-Phase-2-Oral-DGAT-2-Inhibitor.html

    GLOBENEWSWIRE
    09 Jan 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search